Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20299600 | 1.00 | HSD17B10 (0.50) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL16064975 | 1.00 | HSD17B10 (0.50) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL12121160 | 1.00 | HSD17B10 (0.50) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL15174416 | 1.00 | HSD17B10 (0.50) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL1311994 | 1.00 | HSD17B10 (0.50) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL1994228 | 1.00 | HSD17B10 (0.50) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL23525346 | 1.00 | HSD17B10 (0.50) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL14211002 | 0.88 | HSD17B10 (0.50) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL1975652 | 0.88 | CHRM2 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL12201950 | 0.88 | HSD17B10 (0.50) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205167-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SAIL BIOMEDICINES, INC. | 2025-06-26 | — | — | US | disclosed |
| EP-4499607-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | Sail Biomedicines, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119072464-A | Novel ionizable lipids and lipid nanoparticles and methods of use thereof | 赛欧生物医药股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| WO-2023183616-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SENDA BIOSCIENCES, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| WO-2021203028-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3558980-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018115275-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-06-28 | — | — | WO | disclosed |
| US-8735410-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| US-8735410-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| US-20140128612-A1 | DEUTERATED OMEGA DIPHENYLUREA RELATED COMPOUNDS AND INTERMEDIATES | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | disclosed |
| US-20110152297-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Astra Zeneca AB Corporation | 2011-06-23 | — | — | US | disclosed |
| US-20110152297-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Astra Zeneca AB Corporation | 2011-06-23 | — | — | US | disclosed |
| US-20080234263-A1 | Quinazoline Derivatives | ASTRAZENECA (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234263-A1 | Quinazoline Derivatives | ASTRAZENECA (SE) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234263-A1 | Quinazoline Derivatives | EGFR, ERBB2, ERBB3 | HSD17B10 4698/4885CHRM2 379/4885CHRM1 249/4885 |
| US-20250205167-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | PHOSPHO1, SGMS2, SGMS1 | HSD17B10 1781/4885CHRM2 4417/4885CHRM1 4686/4885 |
| US-20110152297-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | HSD17B10 4647/4885CHRM2 787/4885CHRM1 485/4885 |
| US-20140128612-A1 | DEUTERATED OMEGA DIPHENYLUREA RELATED COMPOUNDS AND INTERMEDIATES | PNLIP, PDXK, DGKK | HSD17B10 1216/4885CHRM2 4114/4885CHRM1 4107/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | HSD17B10 815/4885CHRM2 4291/4885CHRM1 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.